Humanin
Humanin is a 24-amino-acid peptide encoded by the mitochondrial genome. Discovered in 2001, it was the first mitochondrial-derived peptide (MDP) identified and is linked to cellular protection, metabolic regulation, and neuroprotection. Humanin levels decline with age and correlate inversely with Alzheimer's disease pathology. A more potent analog called HNG (humanin G) is used in research settings.
FormBlends Peptide Context
Reviewed May 14, 2026Read Humanin peptide guide with the practical follow-up in mind. If the topic involves peptide therapy, the next useful step is usually to verify evidence strength, access rules, pharmacy pathway, total cost, and the personal safety details that only a clinician can review.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
Clinical decision snapshot
Humanin authority snapshot
Humanin is evaluated by mechanism, evidence quality, regulatory status, practical access, and safety questions a licensed clinician would need to review before use.
Evidence signal
Early clinical or translational evidence
Regulatory reality
Not specifically addressed in 2023/2026 regulatory actions
Safety screen
Very limited safety data in humans, Injection site reactions possible, No significant adverse effects reported in animal toxicology studies should be reviewed in context.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
Decision path
What is the supervised-review path for Humanin?
Humanin should be evaluated by evidence quality, safety status, source quality, dosing context, and whether the goal fits a legitimate clinical pathway. This page is a research and decision aid, not a self-prescribing guide.
- Peptide
- Humanin
- Category
- Anti-Aging
- Evidence
- Early clinical or translational evidence
- FDA status
- Not FDA approved
Step 1
Check evidence level
Humanin has compelling preclinical and observational data. A 2020 study in Aging Cell found that centenarians have higher circulating humanin levels than younger controls, suggesting a longevity association. Animal studies show neuroprotection and metabolic benefits. But no human interventional trial has been completed, so we don't know if supplementing humanin produces the same effects seen in mice.
Review evidenceStep 2
Screen safety context
Very limited safety data in humans, Injection site reactions possible, No significant adverse effects reported in animal toxicology studies should be discussed in light of history, dose, and source.
Check side effectsStep 3
Confirm access route
If FormBlends offers access, review the product page and provider pathway before deciding.
Review product accessLast updated: April 6, 2026
Typical Dosage
Not established for clinical use. Research uses HNG analog at doses extrapolated from animal studies. Some practitioners use 1-5 mg subcutaneously daily.
Administration
Subcutaneous injection
Typical Cost
$200-400/month
FDA Status
Not FDA Approved
Half-Life
Not well-characterized. Natural humanin is rapidly degraded by proteases. The HNG analog (with a glycine substitution at position 14) is more resistant to degradation.
Onset of Action
Animal studies show protective effects within hours. No human onset data available.
Bioavailability
Subcutaneous injection. Not orally bioavailable.
About Humanin
Humanin is a 24-amino-acid peptide (MAPRGFSCLLLLTSEIDLPVKRRA) encoded by the 16S ribosomal RNA gene of the mitochondrial genome. Molecular weight: approximately 2,687 Da. It was discovered in 2001 by Nishimoto and colleagues at Keio University in Japan (PMID: 11756463) while searching for genes that protect against Alzheimer's disease.
Humanin was the first mitochondrial-derived peptide (MDP) ever identified. Before its discovery, researchers thought mitochondrial DNA only encoded proteins for the electron transport chain and ribosomes for making those proteins. Humanin showed that mitochondria also produce signaling molecules that communicate with the rest of the cell and the body. This was a conceptual breakthrough.
The neuroprotection finding came first. Humanin protects neurons from amyloid-beta toxicity, which is the hallmark pathology of Alzheimer's disease. In cell culture, neurons treated with humanin survived exposure to amyloid-beta that killed untreated cells. In mouse models of Alzheimer's, humanin analogs reduced cognitive decline.
The longevity connection emerged from population studies. A 2020 study in Aging Cell (PMID: 33089916) measured circulating humanin levels in centenarians (people who lived past 100), their offspring, and age-matched controls. Centenarians and their children had significantly higher humanin levels. This doesn't prove humanin caused their longevity, but it's a strong correlational signal.
The metabolic effects are also interesting. Humanin interacts with IGFBP-3, a protein that modulates insulin-like growth factor signaling. In animal models, humanin treatment improved insulin sensitivity and reduced the metabolic decline associated with aging and high-fat diets.
The main limitation is obvious: no human has been given humanin in a controlled clinical trial. Everything we know about supplementation comes from animal models and cell culture. The centenarian data is observational. We don't know if giving humanin to a 50-year-old will produce any of the benefits suggested by preclinical research.
Practitioners who prescribe humanin typically use HNG, a synthetic analog with a glycine substitution at position 14 that makes it more resistant to enzymatic degradation. Standard research doses range from 1-5 mg injected subcutaneously daily, though these are extrapolated from animal studies and haven't been validated in human dose-response trials.
Store lyophilized humanin at -20C. Reconstitute with bacteriostatic water. The peptide is relatively unstable, so use reconstituted vials within 14 days when stored at 2-8C.
How Humanin Works
Humanin binds to multiple receptors including FPRL1, CNTFR/WSX-1/gp130 complex, and IGFBP-3. Through these interactions, it activates STAT3 signaling (cell survival), inhibits apoptosis (programmed cell death), reduces amyloid-beta toxicity in neurons, improves insulin sensitivity through IGFBP-3 modulation, and protects cells from oxidative stress. It represents a signaling pathway from mitochondria to the rest of the cell, telling the body about mitochondrial health status.
Receptor targets:
Benefits
- Neuroprotective effects against amyloid-beta toxicity
- Protects cells from oxidative stress and apoptosis
- Improves insulin sensitivity through IGFBP-3 pathway
- Levels correlate with longevity in centenarian studies
- May protect cardiovascular cells from ischemic damage
- Anti-inflammatory effects
What Does the Research Say?
Humanin has compelling preclinical and observational data. A 2020 study in Aging Cell found that centenarians have higher circulating humanin levels than younger controls, suggesting a longevity association. Animal studies show neuroprotection and metabolic benefits. But no human interventional trial has been completed, so we don't know if supplementing humanin produces the same effects seen in mice.
Humanin, a mitochondrial-derived peptide, is a novel neuroprotective factor
Journal of Neuroscience, 2001 · DOI · PubMed
Discovery paper showing humanin protects neurons from amyloid-beta-induced cell death, establishing it as the first known mitochondrial-derived protective peptide
PubMed evidence trail
Research sources used to frame this page
For Humanin, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Potential Side Effects
- Very limited safety data in humans
- Injection site reactions possible
- No significant adverse effects reported in animal toxicology studies
Drug Interactions
| Compound | Interaction | Severity |
|---|---|---|
| IGF-1 and growth hormone therapies | Humanin modulates IGFBP-3, which affects IGF-1 signaling. The interaction could be either synergistic or counteractive depending on context. | moderate |
Who Is Humanin For?
Women
No sex-specific data. The centenarian studies included both men and women.
Adults Over 50
The target demographic. Humanin levels decline with age, and the centenarian correlation suggests higher levels may be protective.
Athletes
Not relevant for athletic performance. Not on WADA's prohibited list.
Regulatory Status
FDA Approved
No
Compounding Legal
Yes
2026 HHS Status
Not specifically addressed in 2023/2026 regulatory actions
Available through some compounding pharmacies as a research peptide. Not widely prescribed due to limited human data.
Last verified: 2026-04-06
Stacking Options
Humanin is commonly stacked with the following peptides for enhanced results:
Conditions Addressed
Get Humanin from FormBlends
Pharmaceutical-grade humanin with free physician consultation.
View Product DetailsFind a Humanin Clinic Near You
Browse peptide therapy clinics in your area that offer humanin treatments.
Find Peptide Clinics